Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash & Equivalents (2022 - 2025)

BioXcel Therapeutics has reported Cash & Equivalents over the past 4 years, most recently at $28.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $28.4 million for Q4 2025, down 4.82% from a year ago — trailing twelve months through Dec 2025 was $28.4 million (down 4.82% YoY), and the annual figure for FY2025 was $28.4 million, down 4.82%.
  • Cash & Equivalents for Q4 2025 was $28.4 million at BioXcel Therapeutics, down from $36.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BTAI hit a ceiling of $233.5 million in Q2 2022 and a floor of $17.4 million in Q2 2025.
  • Median Cash & Equivalents over the past 4 years was $69.7 million (2023), compared with a mean of $101.4 million.
  • Peak annual rise in Cash & Equivalents hit 4.82% in 2025, while the deepest fall reached 69.02% in 2025.
  • BioXcel Therapeutics' Cash & Equivalents stood at $193.7 million in 2022, then plummeted by 66.33% to $65.2 million in 2023, then plummeted by 54.23% to $29.9 million in 2024, then fell by 4.82% to $28.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $28.4 million (Q4 2025), $36.2 million (Q3 2025), and $17.4 million (Q2 2025) per Business Quant data.